title: Removal of partial agonism from parathyroid hormone (PTH)-related protein-(7-34)NH2 by substitution of PTH amino acids at positions 10 and 11.
abstract: PTHrP(7-34)NH2 and [D-Trp12]PTHrP(7-34)NH2 have previously been shown to be shown to be more potent antagonists than the corresponding PTH peptide, [Tyr34]bPTH(7-34)NH2. However, these peptides also display partial agonism for adenylate cyclase activity in ROS 17/2.8 cells. In this study, design of a pure potent antagonist of PTH and PTHrP by removal of agonism from PTHrP(7-34)NH2 with retention of antagonist potency was accomplished. Since [Tyr34]bPTH(7-34)NH2 lacks agonist activity, we introduced two amino acids native to the PTH sequence into their respective positions in PTHrP and the potent D-Trp12 analog. [Asn10Leu11]- and [Asn10,leu11,D-Trp12]-PTHrP(7-34)NH2 were found to be 23- and 26-fold more potent as antagonists in ROS cells than PTHrP(7-34)NH2 and [D-Trp12]PTHrP(7-34)NH2, respectively. In addition, these peptides did not display partial agonism, even in an assay based on highly responsive cells pretreated with dexamethasone and pertussis toxin. In contrast, when the PTHrP sequence Asp10,Lys11 was inserted into [Tyr34]hPTH(7-34)NH2, antagonist potency declined by more than 6-fold and PTH-like agonist activity was installed. These results demonstrate that the activation domain of both PTH and PTHrP can be extended to include the 1-12 region and that the 10-12 region, in addition to the N-terminal hexapeptide, is important not only for receptor binding but also for hormonal signal transduction.
authors.affiliation: Parathyroid Hormone Laboratory, Merck Sharp and Dohme Research Laboratories, West Point, PA 19486.
authors.forename: R F
authors.initials: RF
authors.lastname: Nutt
authors.forename: M P
authors.initials: MP
authors.lastname: Caulfield
authors.forename: J J
authors.initials: JJ
authors.lastname: Levy
authors.forename: S W
authors.initials: SW
authors.lastname: Gibbons
authors.forename: M
authors.initials: M
authors.lastname: Rosenblatt
authors.forename: R L
authors.initials: RL
authors.lastname: McKee
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism*; D000595:Amino Acid Sequence; D000818:Animals; D000242:Cyclic AMP / Q000096:biosynthesis; D008969:Molecular Sequence Data; D012516:Osteosarcoma / Q000378:metabolism; D010281:Parathyroid Hormone / Q000037:antagonists & inhibitors*; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments / Q000494:pharmacology*; D011487:Protein Conformation; D011506:Proteins / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D051381:Rats; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured
chemical_list: D010281:Parathyroid Hormone; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments; D011506:Proteins; C064776:parathyroid hormone-related protein (7-34)amide; D000242:Cyclic AMP; D000262:Adenylyl Cyclases